Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : Eternygen Announces the First Closing of its Series A2 Funding Round

10/26/2020 | 05:40am EST

Berlin, Germany, 26 October, 2020:
Eternygen today announced the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment amounting to € 5 m will be used to drive Eternygen's development of novel treatments for non-alcoholic steatohepatitis ('NASH') to the next milestone, i.e. the selection of a preclinical development candidate, the initiation of IND enabling studies as well as growing clinical capabilities within the team.

'At Evotec we are committed to developing disease modifying treatments for metabolic diseases,' Dr Cord Dohrmann, Chief Scientific Officer of Evotec said. 'Eternygen's approach to NASH fits very well as it is focused on the inhibition of INDY, a target with accumulating evidence that is plays an important metabolic role in the development of NASH and related metabolic disorders. Although INDY is not easily tractable via small molecules Eternygen has managed to identify a number of chemical leads which clearly have the potential to be turned into drugs. We are very much encouraged by Eternygen's progress and believe that they will deliver sorely needed drugs to NASH patients who are lacking effective treatment options.'

Evotec has been an investor in Eternygen since paticipating in the company's Series A funding round in 2017.

For further information on the Series A2 funding round, please follow this link to Eternygen's press release (only available in English).

Disclaimer

Evotec SE published this content on 26 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2020 10:39:01 UTC


© Publicnow 2020
All news about EVOTEC SE
12/03EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
12/02EVOTEC : publishes DDup 10 – Evotec's transforming transcriptomics toxicol..
PU
11/30EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
11/29EVOTEC : and Rappta Therapeutics enter discovery and development partnership foc..
PU
11/25EVOTEC : and Rappta Therapeutics enter discovery and development partnership foc..
AQ
11/24EVOTEC : And rappta therapeutics enter discovery and development partnership foc..
EQ
11/20EVOTEC : presents growth drivers of 'Autobahn to Cures' at Capital Markets Day
AQ
11/20EVOTEC : Gets a Buy rating from RBC
MD
11/19EVOTEC : Presents growth drivers of 'autobahn to cures' at capital markets day
EQ
11/18EVOTEC : and STORM Therapeutics leverage INDiGO platform to progress oncology pr..
AQ
More news
Financials
Sales 2020 475 M 576 M 576 M
Net income 2020 22,7 M 27,5 M 27,5 M
Net cash 2020 7,50 M 9,09 M 9,09 M
P/E ratio 2020 183x
Yield 2020 -
Capitalization 4 275 M 5 188 M 5 181 M
EV / Sales 2020 8,99x
EV / Sales 2021 7,66x
Nbr of Employees 3 444
Free-Float 85,1%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 30,67 €
Last Close Price 26,15 €
Spread / Highest target 37,7%
Spread / Average Target 17,3%
Spread / Lowest Target 7,07%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE13.45%5 188
MODERNA, INC.679.75%62 229
LONZA GROUP AG52.83%45 010
CELLTRION, INC.109.94%42 993
SEAGEN INC.56.86%32 484
IQVIA HOLDINGS INC.10.42%32 139